ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RVMD vs ARGX // OPERATING MARGIN

Revolution Medicines Inc. (NASDAQ) VS. argenx SE (NASDAQ) • 15-METRIC TALLY: RVMD 2 — ARGX 7
■ METRIC PARITY
operating-margins
13.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. ARGX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RVMD ARGX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.60% 9.90% -38.50 ARGX /roic <GO>
EV/EBITDA & P/E Valuation — 21.0x — TIE /valuation <GO>
Free Cash Flow Yield -2.24% 2.21% -4.45 ARGX /fcf-yield <GO>
Operating Margin ACTIVE — 13.90% — TIE /operating-margins <GO>
Net Profit Margin — 10.90% — TIE /net-margins <GO>
Revenue Growth (YoY) 15.40% 18.70% -3.30 ARGX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 3.74 +22.26 RVMD /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 ARGX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.8 51.7 -3.90 ARGX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.07 1.02 +0.05 RVMD /macro-sensitivity <GO>
Forward P/E Multiple 34.0x 27.6x +6.40 ARGX /forward-pe <GO>
Enterprise Scale & Market Cap $40.78B $55.72B -$14.94B ARGX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RVMD REV ARGX REV RVMD GROSS % ARGX GROSS % RVMD FCF ARGX FCF
FY 2025 $0 — — — -$913.7M —
FY 2024 $0 — — — -$567.7M —
FY 2023 $11.6M — — — -$351.1M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
ARGX // BETA 1.02